These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: 3TC approved: now for the tough questions.
    Author: Mascolini M.
    Journal: J Int Assoc Physicians AIDS Care; 1995 Dec; 1(11):6-8. PubMed ID: 11363101.
    Abstract:
    Three clinical investigators examine key questions on the use of 3TC/ZDV therapy for patients with HIV infection, including previously-untreated patients. Questions addressed are: 1) Is adding 3TC to the regimens of ZDV-experienced individuals as enticing a strategy as starting 3TC/ZDV in people who are anti-retroviral naive? 2) Will 3TC's in vitro cross-resistance with didanosine (ddI) and zalcitabine (ddC) jeopardize the effectiveness of those latter nucleoside analogs if 3TC is used first? 3) Will 3TC/ZDV be more effective than ddI/ZDV or ddI alone for children?
    [Abstract] [Full Text] [Related] [New Search]